Clinical trial
PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian…
NCT00059618 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00059618 |
|---|---|
| Title | PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer |
| Official title | A Phase I Study Evaluating the Safety and Tolerability of PS-341(Bortezomib)and Carboplatin in Patients With Platinum- and Taxane-Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Millennium Pharmaceuticals, Inc. Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer |
| Intervention type | Drug |
| Interventions | PS-341 (Bortezomib), Carboplatin |
| Enrollment | 21 |
| Start date | Apr 1, 2003 |
| Primary completion | Apr 1, 2007 |
| Completion | Apr 1, 2007 |
| First posted | Apr 30, 2003 |
| Last update posted | Aug 2, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: